Literature DB >> 27508096

Response to 'Dai W et al. Am J Cancer Res 2015;5(10):3270-3275' from the makers of nintedanib.

Claudia-Nanette Gann1, Nassim Morsli2, Xiaoxiang Chen3, José Barrueco4.   

Abstract

Entities:  

Year:  2016        PMID： 27508096      PMCID： PMC4969403     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN： 2156-6976            Impact factor:   6.166


× No keyword cloud information.
  2 in total

1.  Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

Authors:  Martin Reck; Rolf Kaiser; Anders Mellemgaard; Jean-Yves Douillard; Sergey Orlov; Maciej Krzakowski; Joachim von Pawel; Maya Gottfried; Igor Bondarenko; Meilin Liao; Claudia-Nanette Gann; José Barrueco; Birgit Gaschler-Markefski; Silvia Novello
Journal:  Lancet Oncol       Date:  2014-01-09       Impact factor: 41.316

2.  A multi-center phase II study of nintedanib as second-line therapy for patients with advanced non-small-cell lung cancer in China.

Authors:  Wenxin Dai; Bailing Luo; Zhiyong Wu; Juan Chen; Guangqiu Feng; Ping Guan
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.